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The purpose of this study was to investigate whether heart rate 
variability could be reliably assessed in patients with ventricular 
arrhythmias and to evaluate whether it is affected by antiarrhyth· 
mic drugs. The study was based on an analysis of 239 ambulatory 
electrocardiographic (ECG) recordings obtained from 67 patients 
with frequent and complex ventricular arrhythmias enrolled in 
the Antiarrhythmic Drug Evaluation Group (ADEG) study. In 
each recording, after exclusion of premature ventricular com· 
plexes, the number of times during a 24 h period in which two 
consecutive sinus RR intervals differed by more than 50 ms was 
calculated. The total 24 h count from each recording was then 
used as an index of heart rate variability. This method is a reliable 
marker of cardiac parasympathetic activity. 
Recordings were analyzed at baseline (n = 56), during long. 
term treatment with amiodarone (n = 17), f1ecainide (n = 22) or 
propafenone (n = 17) and after washout in selected patients 
(n = 5). Despite the presence of a different number of arrhyth· 
mias, total 24 h counts in the same patient appeared reproducible 
over time (r = 0.83 between two different recordings, n = 49, P < 
0.0001). 
In the last few years, several experimental (1-4) and clinical 
(5,6) studies have shown that signs of reduced vagal activity 
are associated with an enhanced risk of sudden cardiac 
death. Frequent and complex ventricular arrhythmias also 
constitute an independent risk factor for sudden cardiac 
death (7,8), and prevention or reduction of arrhythmias 
might be associated with reduced risk (9,10). However, 
some potent antiarrhythmic drugs may actually increase the 
incidence of death as demonstrated by the Cardiac Arrhyth-
mia Suppression Trial (CAST) (11). The assessment of heart 
rate variability and autonomic control in patients with ar-
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Baseline counts (median 1,698, range 26 to 13,648) were not 
correlated (r = 0.15) with the number of arrhythmias. The three 
antiarrhythmic drugs had a disparate effect on total 24 h counts: 
no change was observed in patients treated with amiodarone 
(median percent change [a%j-8, p = NS), whereas a significant 
(p < 0.025) decrease occurred in patients treated with f1ecainide 
(median a%-56%) or propafenone (median a%-64%). This 
effect was reversible after treatment was discontinued and was not 
related to suppression of arrhythmias because total 24 h counts 
were similar during treatment in the presence and absence of 
frequent arrhythmias. 
These results indicate that heart rate variability can reliably be 
assessed by this total 24 h counts method in patients with frequent 
ventricular arrhythmias. The presence or suppression of arrhyth· 
mias itself did not modify heart rate variability. Class IC antiar· 
rhythmic drugs may significantly affect heart rate variability, and 
this influence may contribute to the overall effect of these agents 
on mortality. 
(J Am Call CardioI1991;17:604-12) 
rhythmia may identify those at greater risk and increase the 
understanding of the detrimental effect of some agents. 
However, to date, this analysis has been limited by technical 
problems. In this study, using 24 h ambulatory electrocar-
diographic recordings of heart rate (12), we adopted a time 
domain approach that appears to provide a sensitive and 
reliable index of cardiac vagal activity (12,13). 
The purpose of this study was threefold. We investigated 
whether 1) this index of heart rate variability is reliable and 
reproducible in patients with frequent ventricular arrhyth-
mia; 2) the suppression of arrhythmia affects heart rate 
variability; and 3) antiarrhythmic drugs with different effects 
on cardiac electrophysiology and contractility (14-16) mod-
ify heart rate variability independently of their antiarrhyth-
mic action. The results have been presented in preliminary 
form elsewhere (17). 
Methods 
We analyzed 24 h ambulatory electrocardiographic 
(ECG) recordings previously obtained from patients enrolled 
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in the multicenter Antiarrhythmic Drug Evaluation Group 
(ADEG) study (18) at baseline, during long-term antiarrhyth-
mic treatment and, in selected patients, after washout. The 
centers participating in the study are listed in the Appendix. 
Protocol of the ADEG Study. The study group consisted 
of patients with cardiac disease: stabilized ischemic heart 
disease (severe stable angina documented by ECG and 
successfully treated by anti anginal drugs excluding verap-
amil and diltiazem or myocardial infarction >8 weeks pre-
viously), dilated cardiomyopathy or hypertrophic cardiomy-
opathy in patients who presented with at least one of the 
following arrhythmias during 24 h ambulatory ECG record-
ing: 1) sustained (> 30 s) or non sustained ventricular tachy-
cardia defined as 4 or more consecutive ventricular ectopic 
beats at a rate> 100 beats/min; 2) runs of 2:3 consecutive 
ventricular ectopic beats; 3) presence of polymorphic ec-
topic couplets; or 4) presence of monomorphic couplets with 
an RR interval <400 ms. 
Criteria for exclusion were: second or third degree atrio-
ventricular (A V) block; sick sinus syndrome (assessed by 
the attending physician from the 12 lead ECG or baseline 
24 h ECG); thyroid dysfunction; hepatic or renal failure; 
concomitant treatment with a beta-adrenergic blocker, ve-
rapamil or diltiazem and a history of unsuccessful treatment 
with one of the three drugs under study. 
Eligible patients (n = 14/) were randomized to receive 
sequences of three antiarrhythmic agents: amiodarone, 
flecainide and propafenone. Long-term treatment with amio-
darone was started with a loading dosage of 600 to 
800 mg/day for 7 days, followed by 200 mg/day, and with 
fixed doses of 200 mg/day for flecainide and 450 mg/day for 
propafenone. 
Response to antiarrhythmic treatment was considered 
satisfactory if the recording during treatment revealed 
1) suppression of sustained and nonsustained ventricular 
tachycardia, 2) reduction >90% of runs of three or four 
ventricular ectopic beats, and 3) >75% reduction of cou-
plets. Reduction in the number of premature ventricular 
complexes was not used as a criterion for response. 
If the response was !lot satisfactory, the drug dose was 
increased to 400 mg/day for amiodarone, 300 mg/day for 
flecainide and 900 mg/day for propafenone. If a patient did 
not respond to the drug or if severe adverse effects occurred 
at either dose, treatment with one of the other two drugs was 
substituted and the follow-up assessment was restarted. If 
the patients did not respond to the second drug, treatment 
with the third one was begun. Each patient was followed up 
for 2:2 years, with periodic examinations at I week and I, 3, 
6, 12, 18, 24 and 36 months of treatment. At each control 
visit, a 24 h ambulatory ECG was recorded, a blood sample 
was taken for estimating plasma concentration of the drug by 
high performance liquid chromatography (19-21) and an 
echocardiogram was performed. Although most of the par-
ticipating centers had bidimensional echocardiographs, only 
M-mode shortening fraction was measured as an index of 
myocardial performance because at the start of patient 
enrollment (in 1985), a few centers had only a monodimen-
sional echocardiograph. 
Measurement of heart rate variability. The tapes sent 
from each of the participating centers for quality control of 
arrhythmia counts were randomly selected and used for 
analysis of heart rate variability. Reel to reel tapes that could 
not be replayed directly on our equipment were copied onto 
cassette format before analysis. All tapes were then replayed 
through a Pathfinder arrhythmia analyzer (Reynolds Medi-
cal) at 120 times the original recording speed. Using the time 
reference track recorded on each tape, the replay speed was 
controlled to within 0.5%. Throughout the analysis, the 
signal was closely monitored by the operator using the 
Pathfinder ECG display to exclude tapes with nonsinus 
rhythms such as atrial fibrillation. 
The trigger section of the analyzer detects individual QRS 
waves in the ECG signal, distinguishing them from P and T 
waves and muscle noise and artifacts accompanying the 
ECG, using a continuously adaptive threshold derived from 
the noise components by independent filtering. The accuracy 
with which each QRS wave can be detected depends on the 
quality of the recorded ECG, but it has been shown (22) that 
with tapes of routine quality false positive and false negative 
errors of detection can be restricted to approximately 12 per 
24 h. Excessive noise, such as would cause QRS waves to be 
missed, automatically inhibits analysis until the noise sub-
sides, at which time analysis is resumed. The Pathfinder 
detects QRS waves on shapes significantly different from the 
subject's normal QRS complex by comparison with a con-
tinuously updated example of this normal complex held in 
the analyzer memory. Such abnormal complexes are indi-
cated as ventricular ectopic beats (23). To monitor more 
gradual alterations in QRS configuration (for example, dur-
ing postural changes), the analyzer provides another thresh-
old that defines how well a QRS wave must match the 
prevailing normal shape to qualify for use in the process of 
updating the normal model. During RR interval analysis, this 
threshold is set low so that only complexes with QRS shapes 
particularly well matched to that of the sinus beat are 
accepted as normal. 
For each ECG complex in the recording, the Pathfinder 
generates an external pulse to signify the detection of a beat. 
If that QRS complex has been identified as of normal (sinus) 
configuration, another pulse is then generated. The pulses 
are passed to a BBC microcomputer programmed for the 
actual RR variability analysis. The assembly language pro-
gram times the arrival of each beat and stores the result with 
0.12 ms (real time) resolution. Subtracting the times between 
successive normal beats allows the calculation of normal-
normal intervals, and subtraction of each interval from its 
predecessor allows the change in interval to be determined. 
Each change in interval is then compared with 50 ms. If an 
increase or decrease >50 ms has occurred, a positive or 
negative count is added to the total being accumulated for 
that hour (12). However, because we previously found no 
significant differences between positive and negative counts 
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(12), the results reported here refer to positive counts (that 
is, increases >50 ms). 
The program also continuously maintains time thresholds 
corresponding to 63% and 175% of the prevailing normal RR 
interval, and beats with intervals outside these limits are 
regarded as premature or pause (a possible missed trigger). 
Although this may lead to the exclusion of some sinus 
intervals, our previous experience indicates that excluding 
such intervals has minimal effects on the sensitivity of the 
test but substantially improves its specificity. Such signifi-
cantly mistimed beats, together with all those indicated by 
the Pathfinder as not normal in shape, are rejected from 
consideration and the interval calculations are restarted from 
the next normal QRS complex. 
The intervals thus excluded, together with all periods 
during which the analyzer was inhibited, are accumulated 
and used to calculate the percent of the record actually 
analyzed. Because not all the recordings were of the same 
duration, the total count in each recording was normalized to 
the equivalent for a complete 24 h record 000% analyzed) to 
facilitate comparisons. We excluded records of < 18 h dura-
tion and those in which <40% was analyzable. The results 
are therefore presented as total 24 h count for each record-
ing. 
Data analysis. Different sets of recordings were used for 
the different purposes of the study. To assess the reproduc-
ibility of heart rate variability, we compared the counts in 
two recordings obtained in the same patient at least 8 days 
apart under similar clinical conditions (n = 49). This in-
cluded comparison between recordings at baseline and after 
drug washout (n = 5), when the number of arrhythmias had 
returned to values similar to those at baseline study and 
between ambulatory ECG recordings obtained during drug 
treatment with a similar number of ventricular arrhythmias 
in the two recordings and similar plasma concentrations of 
the antiarrhythmic agents (n = 44). Such comparisons al-
lowed us to assess the role of the presence of frequent 
ventricular arrhythmias as a possible confounding factor for 
the reproducibility of the recordings in these patients. 
The effect of the three drugs on heart rate variability was 
assessed by determining the changes in the number of counts 
during maintenance treatment (a minimum of 8 days for 
fiecainide and propafenone and 21 days for amiodarone) 
compared with baseline values. Because of the nonnormal 
distribution of the data which became normal after logarith-
mic transformation, statistical analysis was performed with 
use of nonparametric tests on the original data (Kruskal-
Wallis test for group comparisons and Wilcoxon rank test for 
analysis of changes within the same patient) and a paramet-
ric test (paired t test) after logarithmic transformation. 
Correlation between two variables was also performed on 
the transformed data by using the Pearson R coefficient. The 
chi-square statistic with Yates' correction when needed was 
used to compare incidence of events. 
Results 
Study patients. A total of 285 ECG tapes from 76 patients 
were used for the analysis of heart rate variability. Of these 
tapes, 66 were recorded at baseline, 211 at different times 
during treatment with the first drug of the sequence and 8 
after drug washout. Forty-eight 06.7%) of the recordings 
were excluded from the analysis for technical reasons. This 
group included 24 tapes with unacceptable noise and repet-
itive shifts in the amplitude or configuration of the sinus QRS 
complex, nonsinus rhythms or excessively large P and T 
waves that made triggering erratic and unpredictable; 10 
tapes with a duration <18 h; 6 tapes from patients with 
bundle branch block in which consistent recognition of the 
premature ventricular beats was not possible and 8 tapes in 
which the presence of very frequent arrhythmias meant that 
<40% of the tape was analyzable (usually between 30,000 
and 40,000 premature ventricular complexes in the 24 h 
recording period), making a meaningful assessment of heart 
rate variability impossible. 
Characteristics of the 67 patients for which data on heart 
rate variability were obtained from one or more ambulatory 
ECG recording are summarized in Table 1. These patients 
did not differ from the remaining group of patients in the 
Antiarrhythmic Drug Evaluation Group (ADEG) study, 
whose characteristics are also shown in Table 1. The mean 
percent duration of each individual recording available for 
baseline analysis was 83% (range 44% to 99%) and increased 
significantly (p < 0.01) to 90% (range 45% to 99%) because of 
a lower number of arrhythmias for recordings during drug 
treatment. 
Baseline heart rate variability. Fifty-six ambulatory ECG 
recordings were amenable to analysis of baseline heart rate 
variability before antiarrhythmic drug treatment. The me-
dian number of total 24 h counts was 1,698 (range 26 to 
13,648), whereas the median number of arrhythmias in the 
same patients was 3,306 (range 110 to 39,587). Median values 
and range of counts were not significantly different for the 
different cardiac disorders or when different concomitant 
pharmacologic treatments (for example, digitalis or diuretic 
drugs) were taken into account. Counts and number of 
arrhythmias at baseline (n = 56) are plotted on a logarithmic 
scale in Figure 1. There was no significant correlation 
(r = 0.15, p = NS) between these two variables. The nine 
diabetic patients did not have significantly different total 24 h 
counts from those of other patients. 
Reproducibility of the recordings. In the 49 patients in 
whom the long-term reproducibility of heart rate variability 
was assessed (in 44 during drug treatment and in 5 without 
treatment), the median interval between recordings was 192 
days (range 8 to 910). Total 24 h counts in the first and 
second recording in the same patient are plotted on a 
logarithmic scale in Figure 2. There was a high correlation 
between the two recordings (r = 0.83) and a limited scatter of 
values around the line of identity. Because a high correlation 
coefficient does not necessarily imply good agreement be-
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Table 1. Characteristics of 141 Patients in the Antiarrhythmic 
Drug Evaluation Group (ADEG) Study With and Without 
Assessment of Heart Rate Variability (HRV) 
HRV Assessed HVR Not Assessed 
(n = 67) (n = 74) 
Age (yr)* 59 ± 8 58 ± 9 
(36-83) (37-84) 
Male/female 62/5 68/6 
Diagnosis 
Ischemic heart disease 50 (74%) 53 (72%) 
Dilated cardiomyopathy 15 (23%) 20 (27%) 
Hypertrophic cardiomyopathy 2 (3%) 1 (1%) 
Total PVCs124 ht 3.890 3.047 
( 11-39.587) ( 15-39.637) 
Couplets/24 ht 56 40 
(0-3.870) (0-2.251) 
Runs of non sustained VT/24 ht 2 
(0-999) (0-358) 
NYHA functional class 
I 35 (53%) 38 (517<) 
II 27 (40%) 31 (427<) 
III 5 (7%) 5(7%) 
Shortening fraction (%)* 24 ± 9 19 ± 7 
Diabetes 9 (14%) 11 (15%) 
Concomitant therapy 
Digitalis 25 (37%) 29 (397<) 
Diuretics 34 (51%) 35 (48%) 
Other 31 (467<) 35 (487<) 
'Mean ± SD (range): tmedian (range). NYHA = New York Heart Associ-
ation: PVCs = premature ventricular complexes: VT = ventricular tachycardia. 
tween two recordings (24). we further quantified the repro-
ducibility of our data by calculating a coefficient of repeat-
ability, according to the method of Bland and Altman (25), 
Figure 1. Number of premature ventricular complexes (PVC) ver-
sus total 24 h counts in baseline recordings from 56 patients with 
ventricular arrhythmias. Diabetic patients are indicated by closed 
circles. No correlation is demonstrated between the two variables. 
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Figure 2. Individual total 24 h counts on the first (x axis) and the 
second occasion (y axis) in 49 patients with ventricular arrhythmias. 
The line of identity between the two recordings is indicated. 
after logarithmic transformation of the data (Fig. 3). The 
mean of the differences (d) between the 49 pairs of record-
ings was very close to zero (d = 0.03), thus allOWing 
assessment of repeatability. The coefficient of repeatability. 
calculated for all patients, was 0.72; when one outlier of this 
limit was excluded. it was 0.66. This value corresponds to a 
376% increase in counts and to a 76% decrease in counts. 
These values may be considered as limits for a biologically 
important change in heart rate variability. These results 
indicate that our index of heart rate variability, using total 
24 h counts. is reproducible in patients with large numbers of 
ectopic beats and can reliably be used to assess the effect of 
pharmacologic treatment of heart rate variability. 
Effect of antiarrhythmic drugs on heart rate variability 
(Table 2). In 56 patients. ambulatory EeGs obtained at 
baseline and during maintenance treatment with one of the 
three drugs were amenable to analysis. Total counts at 
baseline study were slightly lower for patients subsequently 
treated with amiodarone. but these differences were not 
significant (Kruskal-Wallis test). The three drugs had a 
disparate effect: amiodarone did not modify total 24 h counts 
significantly. whereas both flecainide and propafenone did. 
The median percent change of counts was -8% for amio-
darone (p = NS versus baseline); -56% for flecainide 
(p = 0.005 versus baseline. Wilcoxon signed rank test and 
p = 0.036 paired t test); and -64% for propafenone (p =c 
0.022 versus baseline. Wilcoxon signed rank test. and p = 
0.0085 paired t test). This disparate effect is illustrated in 
Figure 4. in which changes in the number of counts from 
baseline are shown for all three drugs . 
A major (>76%) reduction in the number of counts 
occurred in 6% of patients treated with amiodarone (similar 
to the overall reproducibility datal. 22% treated with 
flecainide (p < 0.05 versus the overall reproducibility data) 
and 35% treated with propafenone (p < 0.05 versus the 
overall reproducibility data). This effect of antiarrhythmic 
drugs on total 24 h counts was not related to changes in mean 
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heart rate, which was decreased during amiodarone treat-
ment (p < 0.001), but remained unchanged during treatment 
with flecainide and propafenone (Table 2). M-mode echocar-
diography performed at baseline study and during treatment 
revealed no significant changes in shortening fraction. No 
relation was found between type of cardiac disease and drug 
effect on total 24 h counts. 
At the time of recording during treatment, the median 
plasma drug concentration in patients treated with amio-
darone was 720 ng/ml (range 156 to 9,990) for the parent 
compound and 640 ng/ml (range 167 to 7,067) for its active 
metabolite desethylamiodarone. For patients treated with 
ftecainide, it was 375 ng/ml (range 54 to 1.199) and for 
patients treated with propafenone, it was 245 ng/ml (range 10 
to 6,303) for the parent compound and 98 ng/ml (range 10 to 
6,984) for it: active metabolite 5-0H-propafenone. No cor-
relation was found between plasma concentration of the drug 
and its effect on total 24 h counts. 
To ascertain further that the changes observed were not 
related to a spontaneous decrease in heart rate variability 
100000 
due to the progression of cardiac disease but were a result of 
the effect of the drug, ambulatory ECGs from five patients 
(four treated with flecainide and one treated with pro-
pafenone) were analyzed after washout (Fig. 5). The effect 
was reversible in four (80%) of the five patients. Although 
the number of patients is small, these data suggest that the 
decrease in counts was a consequence of the antiarrhythmic 
drug treatment. 
Effect of arrhythmia suppression on heart rate variability. 
During follow-up study, mUltiple recordings were obtained 
in 13 patients in whom despite the same antiarrhythmic 
treatment (amiodarone in 5, flecainide in 3 and propafenone 
in 5), no suppression of arrhythmias was observed in one 
recording, whereas a significant reduction in the number of 
arrhythmias was observed during a second recording. This 
group included patients who became responders to a given 
drug only at the higher dosage and those who were initially 
responders but became nonresponders despite continuation 
of treatment at the same dosage, allowing investigation of 
the specific effect of arrhythmia suppression itself on heart 
Table 2. Effect of Three Different Antiarrhythmic Drugs on Total 24 h Counts, Heart Rate and Shortening Fraction 
Days on 
Total 24 h Counts' Heart Rate (beats/min)t Shortening Fraction (%)t 
Treatment* Baseline Treatment Baseline Treatment Baseline Treatment 
Amiodarone 91 816 787 78 ± 12 69 ± 8:j: 21.2 ± 8 20.6 ± 6 
(n = 17) (21-741) (26-13,648) (128-5.449) 
Flecainide 140 1696 680:j: 75 ± 11 n ± 10 24.2 ± 9 25.1 ± 6 
(n = 22) (8-904) (76-8,643) (50-7,834) 
Propafenone 188 1637 601:1: 76 ± 9 76 ± 8 25.6 ± 8 26.3 ± 10 
(n = 17) (11-988) (132-7,059) (10-5,956) 
*Median (range); tmean ± SO; :j:significantly different from baseline (see text). 
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counts in 56 patients with ventricular arrhythmias. Asterisks indicate 
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rate variability by comparison of the total 24 h counts in the 
two recordings. 
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difference in the number of arrhythmias in the responder 
state (median 3.602 premature ventricular complexes/24 h 
for nonresponders and 320 premature ventricular com-
plexes/24 h for responders, p < 0.001. Wilcoxon signed rank 
Figure 5. Individual results from five patients in whom total ~4 h 
counts were measured at baseline (control I. during treatment and 
after drug washout. 
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mean values (:+: standard deviation) when the patients were nonre-
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were responders. Note that although reduction of isolated prema-
ture ventricular complexes (PVC) was not used as a criterion for 
efficacy in the ADEG study. a major decrease in the number of 
premature ventricular complexes is apparent in the responder state. 
However. the number of counts in the two conditions is very 
,imilar. 
testl. the heart rate variability on the two occasions was 
similar. with a median 01'842 counts (range 30 to 5,869) when 
patients were nonresponders and 640 counts (range 64 to 
5,869) when patients were responders, indicating that inde-
pendent of the drug used, suppression of arrhythmias itself 
did not affect heart rate variability. 
Discussion 
We have shown in this study that our method of measur-
ing heart rate variability. counting the number of successive 
RR interval differences >50 ms. can be used reliably even in 
the presence of frequent ventricular ectopic beats. Indeed, 
the number of such beats does not affect the underlying heart 
rate variability as measured in this way. The method pro-
vides a sensitive indicator of cardiac parasympathetic activ-
ity (12.13) and is sufficiently reproducible in individuals with 
similar clinical conditions to reveal any significant effects 
caused by different drugs. We therefore observed the effect 
on cardiac parasympathetic activity of three widely used 
antiarrhythmic agents and found that f1ecainide and pro-
pafenone each produced a significant and marked reduction 
in this component of heart rate variability, whereas there 
was no change with amiodarone. 
Heart rate variability in patients with ventricular arrhyth-
mias. A number of different techniques have been proposed 
to assess heart rate variability. both in the time and fre-
quency domain (12.13.26-32). Although it has been sug-
gested that results using time- and frequency-based analyses 
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are superimposable (33), power spectrum analyses are ex-
tremely sensitive to the presence of arrhythmias, need very 
stable recording conditions and usually cope with only 
relatively short segments of recording. This may render the 
frequency domain approach less suitable for 24 h ambulatory 
monitoring in patients with even small numbers of ventricu-
lar ectopic beats. A time-based approach that recently 
achieved prominence in the analysis of heart rate variability 
uses the standard deviation around the mean heart rate for 
different periods (5,6). This method does not measure the 
same data measured by our counts method because both 
short- and longer-term variations will be included in the 
summary standard deviation. Thus, the standard deviation 
method includes not only purely parasympathetic compo-
nents, but also sympathetic influences on heart rate variabil-
ity. Our method has previously been used by us to identify 
parasympathetic damage in diabetic subjects (12), transplant 
patients (12) and patients after acute myocardial infarction 
(13). We recently improved our original method so that it can 
now handle and exclude even extensive ventricular arrhyth-
mias at 120 times real speed without losing any of the 
essential heart rate variability data (see Methods). 
If meaningful results of the effect of antiarrhythmic agents 
on heart rate variability are to be obtained, the measured 
index must be reproducible. We previously showed (12) that 
our counts method is reproducible in normal and diabetic 
subjects. The data obtained by comparing two recordings in 
the same patient, mostly during drug treatment, show that 
the variability of recordings within the same patient in the 
present study is relatively small (Fig. 2 and 3), indicating that 
even in the presence of frequent ventricular arrhythmias, 
this index of heart rate variability is reliable. 
Some baseline count values were at or below the lower 
end of the normal range. This could be due to the presence 
of significant cardiac disease in this group of patients. 
Patients with cardiac failure and ischemic heart disease may 
have lower heart rate variability than normal subjects (34-
36). However, it is unlikely that any alterations in autonomic 
balance during the acute (13) or subacute (32) phase of 
myocardial infarction contribute to the low count values 
because those patients with a previous myocardial infarction 
were recruited at a stable phase >8 weeks later. Their mean 
count values did not differ from those of patients with other 
types of cardiac disease. 
Effect of antiarrhythmic agents on heart rate variability. 
Antiarrhythmic drugs theoretically may affect heart rate 
variability in several ways. The experimental observation 
(37,38) that the hemodynamic consequence of frequent ar-
rhythmias can alter sympathetic efferent activity at least for 
brief periods of time suggests that arrhythmias themselves 
may lead to an imbalance of autonomic discharge to the 
heart. If this is true, then arrhythmia suppression itself might 
lead to a change in heart rate variability. However, in this 
study, two observations did not support this hypothesis. 
First, there was no correlation between number of counts 
and number of arrhythmias at baseline study (Fig. I). Sec-
ond, and perhaps more important, the count rate appeared 
unaffected when arrhythmias were or were not suppressed 
by the antiarrhythmic treatment (Fig. 6). This observation 
suggests that the presence of arrhythmias themselves or 
their suppression by antiarrhythmic agents does not affect 
cardiac parasympathetic activity. 
Antiarrhythmic agents may, however, alter heart rate 
variability by a direct effect on the autonomic nervous 
system and myocardial contractility. For example, amio-
darone has minimal effects on myocardial performance (14); 
but in experimental animals, it interacts with the autonomic 
nervous system at a central (39) and peripheral (40,41) level. 
Both propafenone and flecainide may reduce myocardial 
performance (15.16) and may have additional vagolytic 
(42,43) and beta-blocking (44) properties that might further 
modulate sympathetic and parasympathetic activity in the 
heart (14,45). The availability of ambulatory ECG recordings 
in a homogeneous group of patients during treatment with 
these three antiarrhythmic drugs has for the first time 
allowed a comparative analysis of the overall effect of these 
agents on heart rate variability. Amiodarone did not modify 
heart rate variability, whereas both flecainide and pro-
pafenone reduced it significantly. The return of the count 
values toward baseline values in most of those patients who 
were studied after interruption of antiarrhythmic treatment 
suggests that these changes are reversible. It might be 
argued that the decrease in heart rate during amiodarone 
treatment but not during therapy with the other two drugs 
affected the results. A very strong inverse relation between 
heart rate and counts would have been required for such a 
decrease in heart rate to mask a decrease in counts similar to 
that produced by the other two drugs. We previously 
showed (12) that the relation between heart rate and counts 
is complex and variable and by no means strong enough to 
account for this possibility. Also, we did not find any 
correlation between drug-induced changes in heart rate and 
counts. 
Accurate measurements of myocardial contractility were 
not available in our study patients because the measured 
fractional shortening on M-mode echocardiography may not 
provide a good enough characterization of cardiac function. 
However, the disparate effect of the three drugs does not 
appear to be related to major changes in cardiac function, 
because shortening fraction was not modified during drug 
treatment, or to a clinical worsening of the patients' condi-
tion, because they continued the same treatment when a 
satisfactory arrhythmia reduction was observed. Class IC 
antiarrhythmic drugs, perhaps through their negative inotro-
pic properties, might cause sympathetic activation and re-
store normal cardiac function but still reduce heart rate 
variability (30) and facilitate the occurrence of malignant 
arrhythmias (2). Indeed, a link between class IC antiarrhyth-
mic drugs and activation of the sympathetic nervous system 
was recently suggested (46) by the observation that their 
proarrhythmic effect may be abolished by the beta-blocking 
agent propranolol. This sympathetic-parasympathetic imbal-
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ance may be undetected by crude indexes (for example, 
absolute values of heart rate), but may be identified with 
more subtle indexes of autonomic balance, such as our 
counts method of measuring heart rate variability. 
Limitations. Before analyzing the possible implications 
of these findings, some limitations of this study need to be 
addressed. This was a retrospective analysis of 24 h ECG 
recordings from patients enrolled in a clinical trial designed 
with other end points. Only some of the Antiarrhythmic 
Drug Evaluation Group (ADEG) study recordings were used 
for this specific analysis. The reproducibility data were 
primarily obtained by comparing two recordings measured 
during drug treatment when the number of arrhythmias was 
usually lower than at baseline study. Although the results 
after drug washout are highly suggestive. the small number 
of patients does not allow any definite conclusion to be 
drawn on the reversibility of the drug effect on heart rate 
variability. It is also unclear whether the type of cardiac 
disease influences the effects of the drugs on heart rate 
variability. 
Implications of the study. With these caveats, some ten-
tative conclusions are warranted. Because low values of one 
measure of heart rate variability (standard deviation) have 
been associated with an increased mortality rate after myo-
cardial infarction (5,6), a decrease in our count index might 
also reflect a poor prognosis. The fact that the count rate 
decreased during treatment with some antiarrhythmic drugs 
may therefore have important implications. An association 
between flecainide therapy and an increased mortality rate 
has already been highlighted in the CAST (11), implying that 
the sudden deaths may have been due to ventricular tachy-
arrhythmias and ventricular fibrillation and hence to a proar-
rhythmic effect of the drug. The late occurrence of these 
deaths during the course of flecainide therapy is. however, 
atypical of proarrhythmic drug effects. This was discussed in 
detail in the consensus statement on the CAST (47), which 
emphasize that many different mechanisms may be respon-
sible for the deaths and that much remains to be elucidated. 
Our new finding that flecainide and propafenone but not 
amiodarone significantly reduced counts, thus suggesting a 
decrease in cardiac vagal activity, may improve the under-
standing of atypical proarrhythmic effects not directly re-
lated to the first phase of therapy. The importance of our 
results to the understanding of the mechanism of action of 
antiarrhythmic agents and their effect on the incidence of 
death remains to be clarified. The method, however, offers 
the prospect of a different approach to the evaluation of 
antiarrhythmic drugs and, hence, of improving antiarrhyth-
mic therapy. 
Appendix 
Antiarrhythmic Drug Evaluation Group (ADEG) 
Steering Committee: P. Giani.' R. Latini.t A. P. Maggioni.+ 
P. J. Schwartz.§ G. Tognoni. t A. Volpd 
Coordination and data monitoring: J. M. Castel, A. Cavalli. V. Giudici. L. 
Gondoni. M. Landolina. E. Riva. R. Roncoroni. G. Zuanetti. 
Data management and statistical analysis: F. Colombo. P. Colombo. M. 
Rocchetti. 
Scientific advisory board: Echocardiography: F. Recusani; Rel'ision of 
major clinical el'ents: A. Selvini;11 Endocrinology: P. Beck Peccoz.' 
Participating Clinical Centers: Aosta (G. Oevoti. G. Begliuomini); Casale 
Monferrato (S. Aletto. O. Corti. M. T. Curti. G. A. Giglio. G. Gozzelino); 
Como (S. Zerboni); Magenta (G. De Pieri, A. Maggi, M. Mereghetti); 
Mantova (L. Simeoni); Milano Policlinico (T. Bertoni. A. Finzi. P. Pagnoni); 
Modena (G. Alfano. F. Melandri. M. C. Tesorieri); Monza (R. Schiavina. F. 
Valagussa, A. Vincenti); Reggio Emilia (U. Guiducci, A. Manari); Rho (P. 
Bana, L. Orvieni); Seriate (G. Ferrario, G. Leoni); Sondalo (R. Bigi); Sondrio 
(G. Cucchi); Torino Ospedale Mauriziano (M. Fazzari); Torino Ospedale 
Molinette (M. Oi Leo. F. Gaita, G. Leone, E. Richiardi); Varese (M. T. 
Fortunati, M. Luvini); Verona Borgo Trento (E. Barbieri, C. Castello, L. 
Rossi): Voghera (P. Gandolfi, C. Pasotti). 
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